Multiple Myeloma and Dendritic Cell Vaccines

AUTOIMMUNE THROMBOCYTOPENIA ,

IV Gribkova, AA Zavyalov

Research Institute for Healthcare Organization and Medical Management, 9 Sharikopodshipnikovskaya str., Moscow, Russian Federation, 115088

For correspondence: Irina Vladimirovna Gribkova, PhD in Biology, 9 Sharikopodshipnikovskaya str., Moscow, Russian Federation, 115088; Tel.: +7(916)078-73-90; e-mail: igribkova@yandex.ru

For citation: Gribkova IV, Zavyalov AA. Multiple Myeloma and Dendritic Cell Vaccines. Clinical oncohematology. 2021;14(3):370–7. (In Russ).

DOI: 10.21320/2500-2139-2021-14-3-370-377

ABSTRACT

Despite advances in the treatment of multiple myeloma, most of patients after its completion retain minimal residual disease (MRD-positive status), which increases the risk of relapse. Antigen-specific immunotherapy of tumors contributes to improving the clinical outcomes in such patients by the killing of cancer drug resistant clone of tumor cells without any damage to normal tissues. Dendritic cells (DC) are antigen-presenting elements with the main function of antigen-capturing, processing, and presenting them to naive T-lymphocytes for the activation of immune response against the captured antigen. The unique ability of DC to activate T-helpers and cytotoxic T-lymphocytes as well as to target thereby the immune reactions was used in developing DC-based tumor immunotherapy. This approach suggests the implementation of the so-called ‘DC-vaccines’. The clinical trials performed by now also showed the results of using DC-vaccines in various tumors including hematological ones. On the whole, according to the studies DC-vaccines are characterized by satisfactory safety profile, moderate immunological activity, and moderate clinical efficacy. The present review provides the results of clinical trials dealing with the use of DC-based vaccines in multiple myeloma patients. Besides, the potentials of improving the clinical efficacy of this therapy are discussed.

Keywords: multiple myeloma, dendritic cells, DC-vaccines, hematological malignancies, immunotherapy.

Received: March 9, 2021

Accepted: June 11, 2021

Read in PDF

Статистика Plumx английский

REFERENCES

  1. Семочкин С.В. Новые ингибиторы протеасомы в терапии множественной миеломы. Онкогематология. 2019;14(2):29–40. doi: 10.17650/1818-8346-2019-14-2-29-40.
    [Semochkin SV. New proteasome inhibitors in the management of multiple myeloma. Onkogematologiya. 2019;14(2):29–40. doi: 10.17650/1818-8346-2019-14-2-29-40. (In Russ)]
  2. Galati D, Zanotta S. Hematologic neoplasms: Dendritic cells vaccines in motion. Clin Immunol. 2017;183:181–90. doi: 10.1016/j.clim.2017.08.016.
  3. Mody N, Dubey S, Sharma R, et al. Dendritic cell-based vaccine research against cancer. Expert Rev Clin Immunol. 2015;11(2):213–32. doi: 10.1586/1744666X.2015.987663.
  4. Banchereau J, Steinman RM. Dendritic cells and the control of immunity. Nature. 1998;392(6673):245–52. doi: 10.1038/32588.
  5. Ito T, Liu YJ, Kadowaki N. Functional diversity and plasticity of human dendritic cell subsets. Int J Hematol. 2005;81(3):188–96. doi: 10.1532/IJH97.05012.
  6. Qian X, Wang X, Jin H. Cell transfer therapy for cancer: past, present, and future. J Immunol Res. 2014;2014:1–9. doi: 10.1155/2014/525913.
  7. Palucka K, Banchereau J. Cancer immunotherapy via dendritic cells. Nat Rev Cancer. 2012;12(4):265–77. doi: 10.1038/nrc3258.
  8. Марков О.В., Миронова Н.Л., Власов В.В., Зенкова М.А. Противоопухолевые вакцины на основе дендритных клеток: от экспериментов на животных моделях до клинических испытаний. Acta Naturae. 2017;9(3):29–41.
    [Markov OV, Mironova NL, Vlasov VV, Zenkova МА. Antitumor vaccines based on dendritic cells: from experiments using animal tumor models to clinical trials. Acta Naturae. 2017;9(3):29–41. (In Russ)]
  9. Богданова И.М., Постовалова Е.А. Клеточная иммунотерапия в онкологии. Противоопухолевые вакцины на основе дендритных клеток. Клиническая и экспериментальная морфология. 2017;22(3):62–73.
    [Bogdanova IM, Postovalova EA. Cellular immunotherapy in oncology. Antitumor vaccines based on dendritic cells. Klinicheskaya i eksperimental’naya morfologiya. 2017;22(3):62–73. (In Russ)]
  10. Yi Q, Szmania S, Freeman J, et al. Optimizing dendritic cell-based immunotherapy in multiple myeloma: intranodal injections of idiotype-pulsed CD40 ligand-matured vaccines led to induction of type-1 and cytotoxic T-cell immune responses in patients. Br J Haematol. 2010;150(5):554–64. doi: 10.1111/j.1365-2141.2010.08286.x.
  11. Hobo W, Strobbe L, Maas F, et al. Immunogenicity of dendritic cells pulsed with MAGE3, Survivin and B-cell maturation antigen mRNA for vaccination of multiple myeloma patients. Cancer Immunol Immunother. 2013;62(8):1381–92. doi: 10.1007/s00262-013-1438-2.
  12. Jung SH, Lee HJ, Lee YK, et al. A phase I clinical study of autologous dendritic cell therapy in patients with relapsed or refractory multiple myeloma. Oncotarget. 2017;8(25):41538–48. doi: 10.18632/oncotarget.14582.
  13. Liso A, Stockerl-Goldstein KE, Auffermann-Gretzinger S, et al. Idiotype vaccination using dendritic cells after autologous peripheral blood progenitor cell transplantation for multiple myeloma. Biol Blood Marrow Transplant. 2000;6(6):621–7. doi: 10.1016/s1083-8791(00)70027-9.
  14. Yi Q, Desikan R, Barlogie B, Munshi N. Optimizing dendritic cell-based immunotherapy in multiple myeloma. Br J Haematol. 2002;117(2):297–305. doi: 10.1046/j.1365-2141.2002.03411.x.
  15. Rosenblatt J, Vasir B, Uhl L, et al. Vaccination with dendritic cell/tumor fusion cells results in cellular and humoral antitumor immune responses in patients with multiple myeloma. Blood. 2011;117(2):393–402. doi: 10.1182/blood-2010-04-277137.
  16. Kitawaki T. DC-based immunotherapy for hematological malignancies. Int J Hematol. 2014;99(2):117–22. doi: 10.1007/s12185-013-1496-4.
  17. Reichardt VL, Okada CY, Liso A, et al. Idiotype vaccination using dendritic cells after autologous peripheral blood stem cell transplantation for multiple myeloma—a feasibility study. Blood. 1999;93(7):2411–9. doi: 10.1182/blood.v93.7.2411.
  18. Massaia M, Borrione P, Battaglio S, et al. Idiotype vaccination in human myeloma: generation of tumor-specific immune responses after high-dose chemotherapy. Blood. 1999;94(2):673–83. doi: 10.1182/blood.v94.2.673.
  19. Lim SH, Bailey-Wood R. Idiotypic protein-pulsed dendritic cell vaccination in multiple myeloma. Int J Cancer. 1999;83(2):215–22. doi: 10.1002/(sici)1097-0215(19991008)83:2<215::aid-ijc12>3.0.co;2-q.
  20. Cull G, Durrant L, Stainer C, et al. Generation of anti-idiotype immune responses following vaccination with idiotype-protein pulsed dendritic cells in myeloma. Br J Haematol. 1999;107(3):648–55. doi: 10.1046/j.1365-2141.1999.01735.x.
  21. Titzer S, Christensen O, Manzke O, et al. Vaccination of multiple myeloma patients with idiotype-pulsed dendritic cells: immunological and clinical aspects. Br J Haematol. 2000;108(4):805–16. doi: 10.1046/j.1365-2141.2000.01958.x.
  22. Lacy MQ, Mandrekar S, Dispenzieri A, et al. Idiotype-pulsed antigen-presenting cells following autologous transplantation for multiple myeloma may be associated with prolonged survival. Am J Hematol. 2009;84(12):799–802. doi: 10.1002/ajh.21560.
  23. Rollig C, Schmidt C, Bornhauser M, et al. Induction of cellular immune responses in patients with stage-I multiple myeloma after vaccination with autologous idiotype-pulsed dendritic cells. J Immunother. 2011;34(1):100–6. doi: 10.1097/CJI.0b013e3181facf48.
  24. Rosenblatt J, Avivi I, Vasir B, et al. Vaccination with dendritic cell/tumor fusions following autologous stem cell transplant induces immunologic and clinical responses in multiple myeloma patients. Clin Cancer Res. 2013;19(13):3640–8. doi: 10.1158/1078-0432.CCR-13-0282.
  25. Palumbo A, Rajkumar SV, San Miguel JF, et al. International Myeloma Working Group consensus statement for the management, treatment, and supportive care of patients with myeloma not eligible for standard autologous stem-cell transplantation. J Clin Oncol. 2014;32(6):587–600. doi: 10.1200/JCO.2013.48.7934.
  26. Richter J, Neparidze N, Zhang L, et al. Clinical regressions and broad immune activation following combination therapy targeting human NKT cells in myeloma. Blood. 2013;121(3):423–30. doi: 10.1182/blood-2012-06-435503.
  27. Kolb HJ, Schattenberg A, Goldman JM, et al.; European Group for Blood and Marrow Transplantation Working Party Chronic Leukemia. Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients. Blood. 1995;86(5):2041–50. doi: 10.1182/blood.v86.5.2041.bloodjournal8652041.
  28. Goulmy Human minor histocompatibility antigens: new concepts for marrow transplantation and adoptive immunotherapy. Immunol Rev. 1997;157(1):125–40. doi: 10.1111/j.1600-065x.1997.tb00978.x.
  29. Oostvogels R, Kneppers E, Minnema MC, et al. Efficacy of host-dendritic cell vaccinations with or without minor histocompatibility antigen loading, combined with donor lymphocyte infusion in multiple myeloma patients. Bone Marrow Transplant. 2017;52(2):228–37. doi: 10.1038/bmt.2016.250.
  30. Franssen LE, Roeven MWH, Hobo W, et al. A phase I/II minor histocompatibility antigen-loaded dendritic cell vaccination trial to safely improve the efficacy of donor lymphocyte infusions in myeloma. Bone Marrow Transplant. 2017;52(10):1378–83. doi: 10.1038/bmt.2017.118.
  31. Weinstock M, Rosenblatt J, Avigan D. Dendritic Cell Therapies for Hematologic Malignancies. Mol Ther Methods Clin Dev. 2017;5:66–75. doi: 10.1016/j.omtm.2017.03.004.
  32. Wilgenhof S, Corthals J, Heirman C, et al. Phase II study of autologous monocyte-derived mRNA electroporated dendritic cells (TriMixDC-MEL) plus ipilimumab in patients with pretreated advanced melanoma. J Clin Oncol. 2016;34(12):1330–8. doi: 10.1200/JCO.2015.63.4121.
  33. Ribas A, Comin-Anduix B, Chmielowski B, et al. Dendritic cell vaccination combined with CTLA4 blockade in patients with metastatic melanoma. Clin Cancer Res. 2009;15(19):6267–76. doi: 10.1158/1078-0432.CCR-09-1254.
  34. Emens LA, Machiels JP, Reilly RT, Jaffee EM. Chemotherapy: friend or foe to cancer vaccines? Curr Opin Mol Ther. 2001;3(1):77–84.
  35. Emens LA. Chemoimmunotherapy. Cancer J. 2010;16(4):295–303. doi: 10.1097/PPO.0b013e3181eb5066.
  36. Formenti SC, Demaria S. Combining radiotherapy and cancer immunotherapy: a paradigm shift. J Natl Cancer Inst. 2013;105(4):256–65. doi: 10.1093/jnci/djs629.
  37. Demaria S, Formenti SC. Radiotherapy effects on anti-tumor immunity: implications for cancer treatment. Front Oncol. 2013;3:128. doi: 10.3389/fonc.2013.00128.
  38. Chi KH, Liu SJ, Li CP, et al. Combination of conformal radiotherapy and intratumoral injection of adoptive dendritic cell immunotherapy in refractory hepatoma. J Immunother. 2005;28(2):129–35. doi: 10.1097/01.cji.0000154248.74383.5e.
  39. Shibamoto Y, Okamoto M, Kobayashi M, et al. Immune-maximizing (IMAX) therapy for cancer: Combination of dendritic cell vaccine and intensity-modulated radiation. Mol Clin Oncol. 2013;1(4):649–54. doi: 10.3892/mco.2013.108.
  40. de Haas N, de Koning C, Spilgies L, et al. Improving cancer immunotherapy by targeting the STATe of MDSCs. Oncoimmunology. 2016;5(7):e1196312. doi: 10.1080/2162402X.2016.1196312.
  41. Butt AQ, Mills KH. Immunosuppressive networks and checkpoints controlling antitumor immunity and their blockade in the development of cancer immunotherapeutics and vaccines. Oncogene. 2014;33(38):4623–31. doi: 10.1038/onc.2013.432.
  42. Грибкова И.В., Завьялов А.А. Терапия Т-лимфоцитами с химерным антигенным рецептором (CAR) В-клеточной неходжкинской лимфомы: возможности и проблемы. Вопросы онкологии. 2021;3. В печати.
    [Gribkova IV, Zavyalov AA. Chimeric antigen receptor T‑cell therapy of B-cell non-Hodgkin’s lymphoma: opportunities and challenges. Voprosy onkologii. 2021;3. In print. (In Russ)]
  43. Грибкова И.В., Завьялов А.А. CAR Т-клетки для лечения хронического лимфоцитарного лейкоза: обзор литературы. Клиническая онкогематология. 2021;14(2):225–30. doi: 10.21320/2500-2139-2021-14-2-225-230.
    [Gribkova IV, Zavyalov AA. CAR-Т Cells for the Treatment of Chronic Lymphocytic Leukemia: Literature Review. Clinical oncohematology. 2021;14(2):225–30. doi: 10.21320/2500-2139-2021-14-2-225-230. (In Russ)]
  44. Stripecke R, Cardoso AA, Pepper KA, et al. Lentiviral vectors for efficient delivery of CD80 and granulocyte-macrophage–colony-stimulating factor in human acute lymphoblastic leukemia and acute myeloid leukemia cells to induce antileukemic immune responses. Blood. 2000;96(4):1317–26. doi: 10.1182/blood.v96.4.1317.
  45. Sundarasetty BS, Singh VK, Salguero G, et al. Lentivirus-induced dendritic cells for immunization against high-risk WT1(+) acute myeloid leukemia. Hum Gene Ther. 2013;24(2):220–37. doi: 10.1089/hum.2012.128.